eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 18
Original paper

Personalized medicine in biomarker identification at their optimal cut-off selection

Tadeusz J. Lewandowski

Health Economics and Healthcare Management Division, Kozminski University, Warsaw, Poland
Gastroenterology Rev 2023; 18 (4): 402–408
Online publish date: 2022/10/18
View full text Get citation
PlumX metrics:
Retrospective exploratory analysis to identify biomarker pairs in the AVAGAST Phase III study. Aim: The main hypothesis of this retrospective exploratory biomarker analysis is the identification of dichotomization levels based on optimal selection driven by the predictive value of single biomarkers. The outcome of interest optimization might unveil additional treatment benefits. Furthermore, testing the biomarker pairs at their optimal cut-off selection might provide the predictive score candidates.

Material and methods
712 plasma 92% and 727 plasma 94% tumor samples of all patients were using Cox model by identifying optimal dichotomization to maximize treatment benefit. A quadrant analysis grouped biomarker pairs into subsets yielded the best clinical benefit. Candidate biomarker score using the nested 2-fold cross-validation method was used to adjust the optimal cut-off selection.

Patients with lower VEGF-R1 at optimal cut-off with low IHER2G showed significant improvement in PFS – first line (HR = 0.62; 95% CI: 0.50 to 0.78). The interaction p-value of the biomarker pair was adjusted at 0.0147094.

The predictive biomarker is a potential candidate for PFS – first line in patients with advanced gastric cancer treated with Bevacizumab.


personalised medicine, cross validation, oncology

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.